Competitive: University of Nottingham: Previous applicants in the last 6 months need not apply This is an exciting MRC-JPIAMR funded project, titled FightAMR: Novel global One Health sur Sutton, United Kingdom

Notice NOT-TR-24-031 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-031 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-033 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-24-036 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to establish a Cancer Immunoprevention Network (CIP-Net) Data and Resource Coordinating Center (CIP-Net DRCC). The overall goals of this NOFO and the companion NOFO (RFA-CA-23-029, Cancer Immunoprevention Network (CIP-Net) Research Projects (UG3/UH3 Clinical Trials Not Allowed)) are to establish an agile and effective network to undertake collaborative research focusing on cancer immunoprevention research. The CIP-Net DRCC will provide overall data and resource coordination, support, and facilitate collaboration across CIP-Net. The CIP-Net DRCC will provide bioinformatic and analytical support, enhance immunoprevention research awareness through scientific communications and meetings, conduct scientific outreach to build immunoprevention bridges across complementary cancer research communities, and foster early career scientist career development.

Notice NOT-HS-24-026 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-26-120 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this NOFO will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the use of new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.

Funding Opportunity RFA-NS-25-024 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.

Funding Opportunity RFA-DK-25-022 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for Recruitment Sites (RS) to enroll adult and/or pediatric patients with Type 1 diabetes (T1D) with, or at high risk of, diabetic nephropathy into a longitudinal cohort study and perform protocol-based research kidney biopsies. These T1D RS will leverage the existing resources of the Kidney Precision Medicine Project (KPMP). T1D RS will collaborate directly with the KPMP to obtain and evaluate kidney biopsies from participants, create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies. Current KPMP RS are not eligible to apply.

Notice NOT-DE-25-038 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-075 from the NIH Guide for Grants and Contracts

Notice NOT-MD-24-022 from the NIH Guide for Grants and Contracts

Notice NOT-DE-25-039 from the NIH Guide for Grants and Contracts

£37890 - £41438 per annum: Rothamsted Research: You will play a pivotal role in supporting the BBSRC funded DSW programme through the provision of bioinformatics ... AL5 2JQ, Herts, UK

Funding Opportunity RFA-HS-24-005 from the NIH Guide for Grants and Contracts. This NOFO invites applications for a National Evaluation Center (NEC) to evaluate AHRQs Healthcare Extension Service: State-based Solutions to Healthcare Improvement (Healthcare Extension Service). The Healthcare Extension Service will accelerate dissemination and implementation of patient-centered outcomes research (PCOR) evidence into healthcare delivery through improvements in healthcare policy, payment, and practice and to reduce healthcare disparities especially among people who receive Medicaid, are uninsured, and other people who are medically underserved. The NEC will: 1) develop data, measures, and methods to assess the range, reach, of effectiveness healthcare extension service models implemented by state cooperative recipients; and 2) conduct a multi-method rapid-cycle formative and summative program evaluation of the Healthcare Extension Service, and the technical assistance and other services provided by the National Coordinating Center (NCC). The goal of the NEC evaluation is to provide a detailed understanding of how healthcare extension services vary across Cooperative recipients, assess the reach effectiveness, and equity of these models, identify contextual factors associated with recipient success, and document the barriers and facilitators to the delivery of healthcare extension services.

Funding Opportunity RFA-HS-24-006 from the NIH Guide for Grants and Contracts. This NOFO invites applications for a National Coordinating Center (NCC) to provide support and guidance to AHRQs Healthcare Extension Service: State-based Solutions to Healthcare Improvement (Healthcare Extension Service). The NCC will provide a wide range of services in 4 main areas: 1) technical assistance, 2) learning networks, 3) communications and dissemination, and 4) leadership and project management. The NCC recipient will work closely with AHRQ and recipients of two related NOFOs: State-based Healthcare Extension Cooperatives to Accelerate Implementation of Actionable Knowledge into Practice (U19) and the National Evaluation Center (NEC) for AHRQ's Healthcare Extension Service: State-based Healthcare Extension Cooperatives to Accelerate Implementation of Actionable Knowledge into Practice (U19).

Competitive: University of Nottingham: The purpose of this role is to work on a Biomedical Research Centre funded project. The aim of this research is to understand the markers and predicto UK Other, United Kingdom

Funding Opportunity PAR-25-051 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

From £43,210, subject to skills and experience, with benefits: The Francis Crick Institute: This project aims to determine the host and viral factors that drive persistent infection London (Central), London (Greater)

Notice NOT-NS-24-085 from the NIH Guide for Grants and Contracts